TY - JOUR
T1 - Clinical outcomes of bioabsorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: Two-year follow-up of the DESSOLVE III trial
AU - Katagiri, Yuki
AU - Onuma, Yoshinobu
AU - Lurz, Philipp
AU - Buszman, Pawel
AU - Piek, Jan J.
AU - Wykrzykowska, Joanna J.
AU - Asano, Taku
AU - Kogame, Norihiro
AU - Takahashi, Kuniaki
AU - Chang, Chun-Chin
AU - de Winter, Robbert J.
AU - Serruys, Patrick W.
AU - Wijns, William
PY - 2020
Y1 - 2020
N2 - Aims: The aim of this study was to assess whether the nine months of cytostatic inhibition by crystalline sirolimus has a beneficial effect in the two-year follow-up in an all-comer population undergoing percutaneous coronary intervention. Methods and results: The DESSOLVE III study (n=1,398) is a prospective, all-comer, multicentre, randomised controlled study (NCT02385279) allocating 703 patients to receive the MiStent drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall, and 695 patients to receive the XIENCE durable polymer everolimus-eluting stent. At two years, the device-oriented composite endpoint (cardiac death, target vessel myocardial infarction [TVMI], and clinically indicated target lesion revascularisation [TLR]) occurred in 8.7% and 8.6% (p=0.958) of patients, and the patient-oriented composite endpoint (all deaths, all MI, and all revascularisations) was observed in 18.5% and 19.6% (p=0.598) of patients in the MiStent and XIENCE arms, respectively. The frequency of TV-MI and clinically indicated TLR was also comparable for both stent types. The rate of definite/probable stent thrombosis was not different in the two arms (0.9% vs 1.3%, p=0.435). Conclusions: In an all-comer population, at two-year follow-up, the use of the MiStent sirolimus-eluting bioabsorbable polymer-coated stent was at least as safe and efficacious as the XIENCE durable polymer stent. The MiStent's potential long-term clinical benefit will be further elucidated after five years of follow-up.
AB - Aims: The aim of this study was to assess whether the nine months of cytostatic inhibition by crystalline sirolimus has a beneficial effect in the two-year follow-up in an all-comer population undergoing percutaneous coronary intervention. Methods and results: The DESSOLVE III study (n=1,398) is a prospective, all-comer, multicentre, randomised controlled study (NCT02385279) allocating 703 patients to receive the MiStent drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall, and 695 patients to receive the XIENCE durable polymer everolimus-eluting stent. At two years, the device-oriented composite endpoint (cardiac death, target vessel myocardial infarction [TVMI], and clinically indicated target lesion revascularisation [TLR]) occurred in 8.7% and 8.6% (p=0.958) of patients, and the patient-oriented composite endpoint (all deaths, all MI, and all revascularisations) was observed in 18.5% and 19.6% (p=0.598) of patients in the MiStent and XIENCE arms, respectively. The frequency of TV-MI and clinically indicated TLR was also comparable for both stent types. The rate of definite/probable stent thrombosis was not different in the two arms (0.9% vs 1.3%, p=0.435). Conclusions: In an all-comer population, at two-year follow-up, the use of the MiStent sirolimus-eluting bioabsorbable polymer-coated stent was at least as safe and efficacious as the XIENCE durable polymer stent. The MiStent's potential long-term clinical benefit will be further elucidated after five years of follow-up.
KW - ACS/NSTE-ACS
KW - Clinical trials
KW - Drug-eluting stent
KW - Stable angina
UR - http://www.scopus.com/inward/record.url?scp=85083381639&partnerID=8YFLogxK
U2 - https://doi.org/10.4244/EIJ-D-18-00944
DO - https://doi.org/10.4244/EIJ-D-18-00944
M3 - Article
C2 - 30719981
SN - 1774-024X
VL - 15
SP - E1366-E1374
JO - EuroIntervention
JF - EuroIntervention
IS - 15
ER -